KEY FINDINGS The global antifungal agents market is chiefly being propelled by factors like poor hygiene habits, supportive policies and programs by government and the development of drug resistance. By the end of the forecast period of 2018-2026, the market is likely to register a CAGR of 3.72%.
MARKET INSIGHTS The antifungal agents market is segmented on the basis of drug types, therapeutic indications, types, applications, and geography.The antifungal agents market on the basis of drug types is segmented into systemic azoles, topical azoles, systemic polyenes, topical polyenes, systemic echinocandins, systemic antimetabolites, other systemic, other topical and other drugs types.
On the basis of therapeutic indications, the market includes aspergillosis market, dermatophytosis, candidiasis and others. Market by type includes prescription and over the counter drugs.The antifungal agents market by application is segregated into topical antifungal drugs and oral drugs. The antifungal drugs market on the basis of geography is segmented into Asia-Pacific, Europe, Rest of the World and North America.
REGIONAL INSIGHTS North America antifungal drugs market possessed a colossal market share of the global antifungal agents market in 2017.A large number of people suffering from fungal infection and advancement in antifungal biopharmaceuticals in the region is upsurging the growth of the antifungal market.
On the other hand, the Asia-Pacific region is projected to be the fastest-growing region for the global antifungal agents market. The Europe antifungal drugs market is also estimated to grow at a healthy CAGR during the forecast period.
COMPETITIVE INSIGHTS The leading market players in the global antifungal agents market are Abbott Laboratories, Strategic Initiatives, Arbor Pharmaceuticals, Inc, Baxter, Astellas Pharma Inc, Bayer Healthcare, Teva Pharmaceuticals, Gilead, GlaxoSmithKline, Johnson & Johnson, Kramer Laboratories, Merck & Co, Novartis, Pfizer, Sanofi-Aventis, and Vertex Pharmaceuticals.
Our reports have been used by over 10K customers, including:
Mycoses Global Clinical Trials Review, H1, 2018 Summary GlobalData’s clinical trial report, “Mycoses Global Clinical Trials Review, H1, 2018" provides an overview of Mycoses clinical trials scenario.This report provides top line data relating to the clinical trials on Mycoses. Report includes...
This study covers the world outlook for Tinea Pedis (Athlete’s Foot) drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These...
This study covers the world outlook for at-home vaginal antifungal treatments across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These...